The survey also showed that high drug costs and artificial intelligence are topmost among the respondent’s concerns.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

In this new role, Flaster will lead Cigna Healthcare’s clinical organization, focusing on initiatives to improve customer ...

As the nation is again under the reigns of a Trump administration and a Republican-led Congress, debates on reducing spending ...

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved ...

Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and ...

A panelist discusses how she proactively addresses safety concerns about neurokinin-targeted therapies through evidence-based ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Here’s what you missed this week on Managed Healthcare Executive. Each Sunday we feature a highlight reel of various articles posted on our website that week.

As with PTSD, people develop acute stress disorder after exposure to traumatic events. The key difference in the diagnostic ...